This document contains several case studies related to anemia management in chronic kidney disease (CKD) patients:
Case 1 describes a hemodialysis patient with pancytopenia due to secondary hyperparathyroidism causing bone marrow fibrosis. Case 2 involves a CKD patient who developed pure red cell aplasia due to erythropoietin antibodies. Case 3 is a patient with occult colon cancer presenting as iron deficiency anemia. Cases 4 and 5 discuss evaluating and treating iron deficiency anemia in CKD patients. The document also reviews causes of erythropoiesis-stimulating agent resistance and options for treating anemia in CKD.
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/Zb6WISbvE2k
Arabic Language version of this lecture is available at:
https://youtu.be/4IvvrbC31Q4
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Sickle cell nephropathy (SCN) is presence of sickled erythrocytes in the renal medulla that result in decreased medullary blood flow, ischemia, microinfarcts and papillary necrosis in the kidneys
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/Zb6WISbvE2k
Arabic Language version of this lecture is available at:
https://youtu.be/4IvvrbC31Q4
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Sickle cell nephropathy (SCN) is presence of sickled erythrocytes in the renal medulla that result in decreased medullary blood flow, ischemia, microinfarcts and papillary necrosis in the kidneys
Anemia Indian scenario In Chronic Kidney Disease Patients Dr Ashutosh Ojha
this is a comprehensive presentation in Post Doctoral Certificate in Nephrology training program. At Gauhati Medical College Hospital ,Dept Of Nephrology.
Presented at Belfast City Hospital Physician's Meeting.
Topic - A case of Focal Segmental Glomerulosclerosis with all the complications of nephrotic syndrome and transplant recurrence of FSGS.
Dr Neerav Goyal discusses the various aspects of acute liver failure that includes the criteria, pre transplant issues, critical care management, overall survival.
Anemia in Chronic Kidney disease is a fascinating area of study both for the Basic scientist and Practising Nephrologist . In this talk , both areas are highlighted with emphasis on erythropoietin .
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
1. Professor Salwa Ibrahim, MD FRCP(Edin)
Cairo University
Case Studies
Anemia management in CKD
4th CKD course, 15-17 May 2016
2. Case 1
• A 45-year-old man with end-stage renal disease on
hemodialysis
• The patient was pancytopenic (white blood cell count 2.3,
hemoglobin 10.3 g/dL, and platelets 85 KU/L)
• He had no history of malignancy or exposure to marrow-
suppressing agents
• His liver function test result was normal except for a high
alkaline phosphatase of 900 IU/L but normal GGT
3. Laboratory Findings
• His intact parathyroid hormone was 1786 pg/mL (normal 50-
60 pg/mL)
• Serum calcium was 7.2 mg/dL (normal 8.5-10.2 mg/Dl)
• Phosphorous was 4.9 mg/dL (normal 2.5-4.5 mg/dL)
4. Definition of Pancytopenia
• Anemia: hemoglobin < 13.5 g/dL (male) or 12 g/dL (female)
• leukopenia: total white cell count < 4.0 x 109/L
• Decrease in all types of white blood cells (revealed by doing a
differential count)
• Thrombocytopenia: platelet count < 150×109/L.
6. Bone Marrow Biopsy
• Bone marrow biopsy revealed fibrotic bone with bony
remodeling, most consistent with renal osteodystrophy
7. Secondary Hyperparathyroidism
• Increased PTH has a direct toxic effect on erythropoietin
synthesis and bone marrow erythroid progenitors
• High PTH promotes the release of cytokines (interleukin-6 and
tumor necrosis factor-α) that stimulate marrow fibroblasts,
resulting in myelofibrosis
• Myelofibrosis has been seen in primary hyperparathyroidism,
so uremic toxin and other factors associated with end-stage
renal disease may play a minor role in marrow fibrosis
8. Treatment of secondary hyperparathyroidism
• Treatment of secondary hyperparathyroidism consists of tight
control of phosphate and administration of active vitamin D, which
inhibits parathyroid cell hyperplasia, suppresses parathyroid
hormone, and increases calcium absorption
• Improvement of hematologic findings often observed after
parathyroidectomy
• However, marrow fibrosis associated with secondary
hyperparathyroidism in patients on dialysis may be irreversible
9. CASE II
• 78-year-old woman had CKD (eGFR 13 ml/min/1.73 m2)
• Was not on dialysis
• Her hemoglobin was 7.7 g/dl
• Eprex dose (4000 U weekly)
10. Follow up
• Her hemoglobin had decreased to 6 g/dl with an
unmeasurable reticulocyte count
• Bone marrow biopsy revealed normal myeloid and
megakaryocyte lines with absent red cell lines
• Positive serum erythropoietin antibody levels
12. Treatment of PRCA
• Eprex was discontinued
• Immunosuppressive therapy was initiated with prednisone
60 mg daily and cyclophosphamide 100 mg daily
• PRBC transfusion
13. • PRCA is a rare syndrome of anaemia associated with low
reticulocyte count, absent bone marrow erythroblasts,
resistance to epoetin therapy and anti-erythropoietin
antibodies
• It has been attributed to the induction of an IgG antibody
directed against the protein moiety of the glycosylated
erythropoietin polypeptide
• PRCA markedly increased after 1998, peaked in 2001 and
then slowly declined thereafter
• 200 cases were described between January 1998 and March
2003
14. CAUSES
• Substitution of polysorbate 80 and glycine for human serum
albumin as stabilizer
• The use of exposed rubber plungers and silicone oil lubricant
in pre-filled syringes
• The shift from the intravenous (i.v.) to the s.c. route of
administration
17. Peginesatide
• It was approved by the U.S. Food and Drug Administration for
treatment of anemia associated with chronic kidney disease
(CKD) in adult patients on dialysis
• On February 2013, Takeda issued a press release indicating
that they were recalling all batches of peginesatide from the
market
• The safety endpoint of cardiovascular events and death was
worse for peginesatide than for darbepoetin
18. Case III
• Male patient, Age 60
• eGFR 55 ml/min, creat 1.5 mg/dl
• Hb 8 g/dl
• Iron studies; TSAT 12% Ferritin 100 mcg/l
19. • Iron deficient BUT anaemia unlikely related to
renal failure (anaemia usually once eGFR < 40)
• DD for other causes
– ? Malignancy
– GIT bleeding
20. Malignancy
• Upper GIT endoscopy was requested, revealed NAD
• Colonoscopy revealed Cancer colon
21. Case IV
• 30 female
• ESRD on HDx
• Aranesp 20 mcg SC weekly
• eGFR 5, creat 7 mg/dl
• Hb 8 g/dl MCV 70
• Iron studies: TSAT % 11 Ferritin 100 mcg/l
22. Diagnosis
• Microcytic Anaemia
• Iron deficient
• Rule out other causes then
– Correct Iron with IV Iron infusion
– Re-check bloods. Once iron OK, may need to increase EPO
24. Iron studies
• Ferritin
– Iron storage protein, giving an indirect measurement of
stored iron
– ↓ ferritin always Iron def, but high in inflammation
(inflammatory marker)
• Transferrin
– Transports iron from stores to the bone marrow.
• Transferrin saturation
– Gives a measure of the iron available to bone marow
– Useful to detect functional iron deficiency
25. Iron studies
• Reticulocyte hemoglobin content: less than 29-32 pg/cell is
indicative of iron deficiency
• The percentage of hypochromic red cells: < 6% is indicative of
iron deficiency
28. Iron added to dialysis solution
• Ferric pyrophosphate citrate (triferic)
• Phase III results showed reduction in ESA doses
29. Iron sucrose (Venofer)
• A popular option, the typical
dosing for Venofer is 100mg iv
dialysis x 10 doses
• Venofer offer fairly rapid release
of iron
30. low-molecular weight iron dextran (CosmoFer)
• Risk of adverse events is so
much lower
• Is given as an intravenous
infusion containing any dose up
to 2000 mg of iron depending
upon the patients’ calculated
iron deficit
31. Ferric carboxymaltose
• Is administered as an
intravenous bolus (containing
500 mg elemental iron) or
intravenous infusion over 30
minutes (containing 1 g of
elemental iron)
32.
33. The increase in haemoglobin concentration
was significantly greater in both IS and FCM compared
with ID (P = 0.04 and <0.01, resp.).
34. Safety of IV iron
• Anaphylaxis
• Infections: iron is vital for growth of microorganisms
• Oxidation: iron is highly oxidative substance that can
promote atherosclerosis
35. Case V
• 54 year-old Male ESRD patient on regular HDx
• Hemoglobin level is 6.7 g/dl
• Serum ferritin 74 mcg/l, TSAT 7%
• Received IV iron 1000 mg
36. • On follow up : hemoglobin level 8 g/dl, TSAT 35 % and serum
ferritin 350 mcg/l
• EPO given 4000 u sc thrice weekly
• After one month Hb was 8.3 g/dl, so EPO dose increased by
50% to 6000u thrice weekly
• Still on follow up, hemoglobin level did not reach the target
despite reaching EPO dose 10.000 U thrice weekly
37. ESA resistance
• 300 IU/Kg/week SC Epo
• 450 IU/Kg/week IV Epo
• 1.5 mcg/Kg/ week darbepoetin
38. Causes of EPO not working
• Iron deficiency ** most common **
• B12 & Folate deficiency
• Inflammation
• ACE inhibitors
• Hyperparathyroidism – bone marrow fibrosis
• Aluminium toxicity
• Inadequate dialysis
• Malignancies, including multiple myeloma
39. Transfuse or not
• In CKD patients wishing to go for renal transplant,
PRBCs transfusion should be avoided
• Given only in severe symptomatic anemia